Biological therapies for asthma
Five to 10% of asthma patients remain symptomatic and/or have asthma attacks despite adequate inhaled and systemic therapy. Eosinophilic, type 2 airway inflammation is seen in half of these patients with severe asthma. There is now convincing evidence that type 2 inflammation drives susceptibility t...
主要な著者: | Couillard Castonguay, S, Pavord, I |
---|---|
その他の著者: | Janes, S |
フォーマット: | Book section |
言語: | English |
出版事項: |
Elsevier
2021
|
類似資料
-
Fractional exhaled nitric oxide non-suppression in asthma
著者:: Couillard Castonguay, S
出版事項: (2021) -
Predicting the benefits of type-2 targeted anti-inflammatory treatment with the prototype OxfoRd Asthma attaCk risk scaLE (ORACLE)
著者:: Couillard Castonguay, S, 等
出版事項: (2022) -
Fluticasone furoate: CAPTAIN of fluticasones in type 2 inflammatory asthma
著者:: Couillard, S, 等
出版事項: (2022) -
Asthma in pregnancy: An update
著者:: Couillard, S, 等
出版事項: (2020) -
How I do it: workup of severe asthma
著者:: Couillard, S, 等
出版事項: (2021)